Cargando…

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial

IMPORTANCE: Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. OBJECTIVE: To evaluate the efficacy and safety of a pharmaceutical formulation of cannabidiol, 10 and 20 mg/kg/d, vs p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Ian, Scheffer, Ingrid E., Gunning, Boudewijn, Sanchez-Carpintero, Rocio, Gil-Nagel, Antonio, Perry, M. Scott, Saneto, Russell P., Checketts, Daniel, Dunayevich, Eduardo, Knappertz, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052786/ https://www.ncbi.nlm.nih.gov/pubmed/32119035 http://dx.doi.org/10.1001/jamaneurol.2020.0073

Ejemplares similares

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
por: Devinsky, Orrin, et al.
Publicado: (2018)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)
Publicado: (2020)

Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol
por: Xu, Changqing, et al.
Publicado: (2021)

Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain
por: Gil-Nagel, Antonio, et al.
Publicado: (2023)

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea
por: Koo, Chung Mo, et al.
Publicado: (2020)

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial
por: Nabbout, Rima, et al.
Publicado: (2020)

Convulsive Seizures
por: Kahn, Eugen
Publicado: (1943)

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice
por: Patra, Pabitra Hriday, et al.
Publicado: (2020)

Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

Cardiac arrhythmias in Dravet syndrome: an observational multicenter study
por: Shmuely, Sharon, et al.
Publicado: (2020)

Seizure reduction with fluoxetine in an adult woman with Dravet syndrome
por: Meador, Kimford J.
Publicado: (2014)

Placebo-Controlled Trial of Daily Oral Cannabidiol as Adjunctive Treatment for Cats with Chronic Gingivostomatitis
por: Coelho, Joana Chambel, et al.
Publicado: (2023)

Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis
por: Sullivan, Joseph, et al.
Publicado: (2021)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome
por: Chuang, Shu-Hui, et al.
Publicado: (2021)

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial
por: Watkins, Paul B., et al.
Publicado: (2020)

Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial
por: Dixon, T., et al.
Publicado: (2023)

Seizure control in a patient with Dravet syndrome and cystic fibrosis()
por: Schmalbach, Barbara, et al.
Publicado: (2013)

Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
por: Silvinato, Antônio, et al.
Publicado: (2022)

Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients
por: Schoonjans, A., et al.
Publicado: (2016)

Prevalence and mortality of epilepsies with convulsive and non-convulsive seizures in Kilifi, Kenya
por: Kariuki, Symon M, et al.
Publicado: (2021)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
por: Hollenack, Kelly, et al.
Publicado: (2021)

Perampanel Reduces Hyperthermia-Induced Seizures in Dravet Syndrome Mouse Model
por: Ho, Shih-Yin, et al.
Publicado: (2021)

A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
por: Strzelczyk, Adam, et al.
Publicado: (2022)

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models
por: Patra, Pabitra Hriday, et al.
Publicado: (2018)

Caregivers’ Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study
por: Marshall, Jade, et al.
Publicado: (2023)

International consensus on diagnosis and management of Dravet syndrome
por: Wirrell, Elaine C., et al.
Publicado: (2022)

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
por: Griffin, Aliesha, et al.
Publicado: (2018)

Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome
por: Wong, Jennifer C., et al.
Publicado: (2019)

Augmented Reticular Thalamic Bursting and Seizures in Scn1a-Dravet Syndrome
por: Ritter-Makinson, Stefanie, et al.
Publicado: (2019)

Augmented Reticular Thalamic Bursting and Seizures in Scn1a-Dravet Syndrome
por: Ritter-Makinson, Stefanie, et al.
Publicado: (2019)

Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials
por: Li, Wenhui, et al.
Publicado: (2021)

The Charlotte Project: Recommendations for patient-reported outcomes and clinical parameters in Dravet syndrome through a qualitative and Delphi consensus study
por: Aledo-Serrano, Ángel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1u97govic37ubi6fhdfr3gagrj